BCL2 and leukemia: BCL2, an inhibitor of the mitochondrial apoptosis pathway, is the founding member of a large family of BH-domain-containing proteins with activities upstream of caspase activation.BCL2 has emerged as a potential therapeutic target in both leukemia [26, 27] and solid tumors [28].